カンピロバクター・ジェユニ菌による腸炎は,猫から人間に感染する.

Activated Cellular Immunity in Chronic Hepatitis C.

Hematology (Amsterdam, Netherlands)·2016

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Alimentary pharmacology & therapeutics·2015

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Journal of viral hepatitis·2013

Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.

Journal of viral hepatitis·2013

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2011

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Journal of viral hepatitis·2011

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Sustained Type 2 Diabetes Remission and Metabolic Health Through Intensive Lifestyle Intervention: A Case Report With a Nine-Year Follow-Up.

Cureus·2026

Case Report: Uremia secondary to acute pyelonephritis in a patient with type 2 diabetes mellitus.

Frontiers in medicine·2026

A study on the effects of a whole grain diet combined with short duration exercise on postprandial glucose levels in overweight and obese adults.

Frontiers in nutrition·2026

Association of Early Supplemental Parenteral Nutrition with Clinical Outcomes in Patients with Traumatic Brain Injury.

Journal of Korean Neurosurgical Society·2026

The gut-microbiota-brain axis mediates the neuroprotective effects of exercise against microgravity-induced cognitive impairment.

Experimental neurology·2026

Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

Journal of cachexia, sarcopenia and muscle·2026

関連する実験動画

カンピロバクター・ジェユニ菌による腸炎は,猫から人間に感染する.

関連する概念動画

Activated Cellular Immunity in Chronic Hepatitis C.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Sustained Type 2 Diabetes Remission and Metabolic Health Through Intensive Lifestyle Intervention: A Case Report With a Nine-Year Follow-Up.

Case Report: Uremia secondary to acute pyelonephritis in a patient with type 2 diabetes mellitus.

A study on the effects of a whole grain diet combined with short duration exercise on postprandial glucose levels in overweight and obese adults.

Association of Early Supplemental Parenteral Nutrition with Clinical Outcomes in Patients with Traumatic Brain Injury.

The gut-microbiota-brain axis mediates the neuroprotective effects of exercise against microgravity-induced cognitive impairment.

Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.

関連する実験動画

カンピロバクター・ジェユニ菌による腸炎は,猫から人間に感染する.

関連する概念動画

関連記事